Eloxx Pharmaceuticals (ELOX) 10-Q 13 Nov 23 2023 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2023	Nov. 08, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Trading Symbol	ELOX
Entity Registrant Name	ELOXX PHARMACEUTICALS, INC.
Entity Central Index Key	0001035354
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity File Number	001-31326
Entity Tax Identification Number	84-1368850
Entity Address, Address Line One	480 Arsenal Way
Entity Address, City or Town	Watertown
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02472
City Area Code	781
Local Phone Number	577-5300
Entity Incorporation, State or Country Code	DE
Entity Shell Company	false
Entity Current Reporting Status	Yes
Title of 12(b) Security	Common Stock, $0.01 par value per share
Entity Interactive Data Current	Yes
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		3,143,390

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 4,775	$ 19,207
Restricted cash	219	261
Prepaid expenses and other current assets	635	661
Total current assets	5,629	20,129
Property and equipment, net	107	169
Operating lease right-of-use asset	306	825
Total assets	6,042	21,123
Current liabilities:
Accounts payable	3,134	3,020
Accrued expenses	2,442	2,799
Current portion of long-term debt	2,819	3,980
Advances from collaboration partners	12,966	12,535
Warrant liabilities	1,695	0
Current portion of operating lease liability	315	712
Derivative liabilities	95	45
Total current liabilities	23,466	23,091
Long-term debt, net of current portion	2,621	8,557
Operating lease liability	3	135
Total liabilities	26,090	31,783
Commitments and contingencies
Stockholders' deficit equity:
Preferred stock, $0.01 par value per share, 5,000,000 shares authorized, no shares issued or outstanding as of September 30, 2023 and December 31, 2022	0	0
Common stock, $0.01 par value per share, 500,000,000 shares authorized, 3,068,390 and 2,166,356 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	31	22
Additional paid-in capital	268,472	263,706
Accumulated deficit	(288,551)	(274,388)
Total stockholders' deficit	(20,048)	(10,660)
Total liabilities and stockholders' deficit	$ 6,042	$ 21,123

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred Stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	3,068,390	3,068,390
Common stock, shares outstanding	2,166,356	2,166,356

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 1,250	$ 4,880	$ 7,076	$ 20,430
General and administrative	2,387	2,262	6,184	7,961
Total operating expenses	3,637	7,142	13,260	28,391
Loss from operations	(3,637)	(7,142)	(13,260)	(28,391)
Other (income) expense, net	(45)	366	903	1,355
Net loss	$ (3,592)	$ (7,508)	$ (14,163)	$ (29,746)
Net loss per share, basic	$ (1.31)	$ (3.47)	$ (5.96)	$ (13.73)
Net loss per share, diluted	$ (1.31)	$ (3.47)	$ (5.96)	$ (13.73)
Weighted average number of shares of common stock used in computing net loss per share, basic	2,747,687	2,166,404	2,377,599	2,166,344
Weighted average number of shares of common stock used in computing net loss per share, diluted	2,747,687	2,166,404	2,377,599	2,166,344

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net loss			$ (14,163)	$ (29,746)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation			1,625	2,380
Depreciation			40	67
Amortization of operating lease right-of-use asset			519	450
Amortization of debt discount			217	397
Change in fair value of derivative liabilities	$ 20	$ (50)	50	116
Change in fair value of warrant liabilities	(273)	0	(273)	0
Loss on extinguishment of debt			406	0
Loss on issuance of common stock	231	0	231	0
Gain on disposal of property and equipment			(255)	0
Changes in operating assets and liabilities:
Prepaid expenses and other assets			26	59
Accounts payable			133	216
Accrued expenses			(357)	322
Operating lease liabilities			(529)	(445)
Net cash used in operating activities			(12,330)	(26,184)
Cash flows from investing activities:
Proceeds from sale of property and equipment			258	0
Purchases of property and equipment			0	(66)
Net cash provided by (used in) investing activities			258	(66)
Cash flows from financing activities:
Proceeds from the issuance of common stock, pre-funded warrants, and common stock warrants from the September 2023 Offering, net of issuing costs			1,737	0
Sale of common stock through ATM, net of issuance costs	1,722		3,150	0
Repayment of term loan principal			(7,720)	0
Proceeds from advances from collaboration partners			431	8,500
Net cash (used in) provided by financing activities			(2,402)	8,500
Decrease in cash, cash equivalents and restricted cash			(14,474)	(17,750)
Cash, cash equivalents and restricted cash at the beginning of the period			19,468	42,567
Cash, cash equivalents and restricted cash at the end of the period	4,994	24,817	4,994	24,817
Reconciliation of cash, cash equivalents and restricted cash to condensed consolidated balance sheets:
Cash and cash equivalents	4,775	24,554	4,775	24,554
Restricted cash	219	263	219	263
Total cash, cash equivalents and restricted cash	$ 4,994	$ 24,817	4,994	24,817
Supplemental disclosure of cash flow activities:
Cash paid for interest			$ 819	$ 968

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' (Deficit) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Stock Subscription Receivable [Member]	Treasury Stock [Member]	Accumulated deficit [Member]
Balance at Dec. 31, 2021	$ 22,384	$ 22	$ 262,875		$ (2,190)	$ (238,323)
Balance, shares at Dec. 31, 2021		2,166,248			(10,535)
Vesting of restricted stock units, shares		78
Stock-based compensation expense	922		922
Net loss	(11,620)					(11,620)
Balance at Mar. 31, 2022	11,686	$ 22	263,797		$ (2,190)	(249,943)
Balance, shares at Mar. 31, 2022		2,166,326			(10,535)
Balance at Dec. 31, 2021	22,384	$ 22	262,875		$ (2,190)	(238,323)
Balance, shares at Dec. 31, 2021		2,166,248			(10,535)
Sale of common stock through ATM, net of issuance costs	0
Net loss	(29,746)
Balance at Sep. 30, 2022	(4,982)	$ 22	265,255		$ (2,190)	(268,069)
Balance, shares at Sep. 30, 2022		2,166,404
Balance at Mar. 31, 2022	11,686	$ 22	263,797		$ (2,190)	(249,943)
Balance, shares at Mar. 31, 2022		2,166,326			(10,535)
Vesting of restricted stock units, shares		78
Stock-based compensation expense	744		744
Net loss	(10,618)					(10,618)
Balance at Jun. 30, 2022	1,812	$ 22	264,541		$ (2,190)	(260,561)
Balance, shares at Jun. 30, 2022		2,166,404
Stock-based compensation expense	714		714
Net loss	(7,508)					(7,508)
Balance at Sep. 30, 2022	(4,982)	$ 22	265,255		$ (2,190)	(268,069)
Balance, shares at Sep. 30, 2022		2,166,404
Balance at Dec. 31, 2022	$ (10,660)	$ 22	263,706			(274,388)
Balance, shares at Dec. 31, 2022	2,166,356	2,166,356
Stock-based compensation expense	$ 597		597
Net loss	(6,230)					(6,230)
Balance at Mar. 31, 2023	16,293	$ 22	264,303			(280,618)
Balance, shares at Mar. 31, 2023		2,166,356
Balance at Dec. 31, 2022	$ (10,660)	$ 22	263,706			(274,388)
Balance, shares at Dec. 31, 2022	2,166,356	2,166,356
Balance at Jun. 30, 2023	$ (18,596)	$ 25	266,379	$ (41)		(284,959)
Balance, shares at Jun. 30, 2023		2,492,666			(10,535)
Balance at Dec. 31, 2022	$ (10,660)	$ 22	263,706			(274,388)
Balance, shares at Dec. 31, 2022	2,166,356	2,166,356
Sale of common stock through ATM, net of issuance costs	$ 3,150
Net loss	(14,163)
Balance at Sep. 30, 2023	$ (20,048)	$ 31	268,472			(288,551)
Balance, shares at Sep. 30, 2023	2,166,356	3,068,390			(10,535)
Balance at Mar. 31, 2023	$ 16,293	$ 22	264,303			(280,618)
Balance, shares at Mar. 31, 2023		2,166,356
Sale of common stock through ATM, net of issuance costs	1,428	$ 3	1,466	(41)
Sale of common stock through ATM, net of issuance costs, Share		326,310
Stock-based compensation expense	610		610
Issuance of shares upon public offering, shares		326,310
Net loss	(4,341)					(4,341)
Balance at Jun. 30, 2023	(18,596)	$ 25	266,379	(41)		(284,959)
Balance, shares at Jun. 30, 2023		2,492,666			(10,535)
Issuance of common stock related to September 2023 Registered Direct Offering, net of initial common warrant liability of $1.9 million and issuance costs of $235		$ 3	(3)
Issuance of common stock related to September 2023 Registered Direct Offering, net of initial common warrant liability of $1.9 million and issuance costs of $235, shares		305,590
Sale of common stock through ATM, net of issuance costs	1,722	$ 3	1,678	$ 41
Sale of common stock through ATM, net of issuance costs, Share		270,134
Stock-based compensation expense	418		418
Issuance of shares upon public offering, shares		270,134
Net loss	(3,592)					(3,592)
Balance at Sep. 30, 2023	$ (20,048)	$ 31	$ 268,472			$ (288,551)
Balance, shares at Sep. 30, 2023	2,166,356	3,068,390			(10,535)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' (Deficit) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Sep. 30, 2022
Statement of Stockholders' Equity [Abstract]
Sale of common stock through ATM, net of issuance costs	$ 124	$ 228	$ 263

Nature of the Business

Nature of the Business	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business	1. Nature of the Business Eloxx Pharmaceuticals, Inc., together with its subsidiaries (collectively “Eloxx” or the “Company”), is a clinical-stage biopharmaceutical company engaged in the science of ribosomal modulation. The Company is developing novel small molecule drug candidates from its library of unique Ribosome Modulating Agents (“RMAs”) and Eukaryotic Ribosomal Selective Glycosides (“ERSGs”) for the treatment of a subset of rare and ultra-rare diseases and cancers characterized by genetic mutations that cause defects in protein translation. Specifically, the Company is targeting restoration of functional proteins in patients with premature stop codon mutations and ribosomal mutations. Premature stop codons are point mutations that disrupt the stability of the impacted messenger RNA (mRNA) and the protein synthesis from that mRNA. Additionally, certain mutations of the ribosome disrupt normal protein translation and are drivers of a subset of cancers. On April 1, 2021, the Company acquired Zikani Therapeutics, Inc. (“Zikani”), a preclinical stage biopharmaceutical company engaged in the science of ribosome modulation, leveraging its innovative TURBO-ZMTM chemistry technology platform to develop novel ribosome modulating agents (“RMAs”). The TURBO-ZMTM platform is designed to enable rapid synthesis of novel macrolides that can be optimized to modulate the human, bacterial or viral ribosomes to treat rare diseases and cancers with certain ribonucleic acid (“RNA”) and ribosomal mutations. The Company is headquartered in Watertown, Massachusetts, with additional operations in Israel and Australia. Liquidity and Going Concern The Company has a history of net losses and negative cash flows from operating activities since inception and, as of September 30, 2023, had an accumulated deficit of $ 288.6 million. The Company expects to continue to incur net losses and negative cash flows from its operations for the foreseeable future. The Company has not generated revenue from the sale of any product or service and does not expect to generate significant revenue unless it obtains marketing approval for and commercializes one or more of its product candidates currently in development. Successful transition to profitable operations is dependent upon achieving a level of revenue adequate to support the Company’s cost structure. The Company has financed its operations primarily from the sale of equity securities and to a lesser extent, loans and g rants. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional capital to fund its operations. In addition, as disclosed in Note 6, in September 2021, the Company entered into the Hercules Loan (as defined below) for an aggregate principal amount of up to $ 30.0 million of which $ 12.5 million had been funded as of December 31, 2022 and effective March 7, 2023, the Company and Hercules agreed to amend the terms of the agreement, and the Company repaid $ 7.5 million of principal. The Hercules Loan Agreement contains customary affirmative and negative covenants, which among others further described in Note 5, require the Company to maintain at all times a minimum qualified cash balance net of qualified accounts payable (as defined in the Hercules Loa n Agreement). On March 7, 2023, the minimum qualified cash balance debt covenant was decreased from $ 10.0 million to $ 2.25 million p lus the amount of accounts payable that have not been paid within 180 days (the “minimum qualified cash balance amount”) and, on November 10, 2023, the Hercules Loan Agreement was amended to temporarily reduce the minimum qualified cash balance amount to $2.25 million for the period from November 15, 2023 through December 15, 2023, unless extended by Hercules in its sole discretion. After December 15, 2023, the minimum level of qualified cash will revert to $2.25 million plus the amount of accounts payable that have not been paid within 180 days. As of September 30, 2023, the Company was in compliance with all debt covenants. However, the inherent uncertainties described above may impact the Company’s ability to remain in compliance with these covenants over the next 12 months. If the Company breaches its financial covenants and fails to secure a waiver or forbearance from the third-party lender, such breach or failure could accelerate the repayment of the outstanding borrowings under the Hercules Loan Agreement or the exercise of other rights or remedies the third-party lender may have under applicable law. No assurance can be provided a waiver or forbearance will be granted or the outstanding borrowings under the Hercules Loan Agreement, will be successfully refinanced on terms that are acceptable to the Company. The Company believes that its cash and cash equivalents of $ 4.8 million at September 30, 2023 will not be sufficient to maintain its current and planned operations for at least the next 12 months following the filing of this Quarterly Report on Form 10-Q. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. However, based on the Company’s current working capital, anticipated operating expenses and net losses and the uncertainties surrounding its ability to raise additional capital as needed, as discussed below, the Company believes that these conditions, in aggregate, raise substantial doubt about its ability to continue as a going concern for one year after the date these condensed consolidated financial statements are issued. Management intends to fund future operations through private or public debt or equity financing transactions and may seek additional capital through arrangements with strategic partners or from other sources. The availability of sufficient funding to alleviate the conditions that raise substantial doubt are not within management’s control and cannot be assessed as being probable of occurring. If the Company is unable to obtain adequate financing, it will evaluate options, which may include reducing or deferring operating expenses, which may have a material adverse effect on the Company’s operations and future prospects.

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	2. Basis of Presentation and Significant Accounting Policies The Company has prepared the accompanying unaudited interim condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) promulgated by the Financial Accounting Standards Board (“FASB”). Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted, as permitted by such rules and regulations. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company’s financial position, results of operations, and cash flows for the interim periods ended September 30, 2023 and 2022. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2022, and the notes thereto, which are included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 31, 2023 (the “2022 Annual Report”). The significant accounting policies used in the preparation of these condensed consolidated financial statements are consistent with those described in the Company’s audited consolidated financial statements as of and for the year ended December 31, 2022, and the notes thereto, in the Company’s 2022 Annual Report. The Company records stock issuances at the effective date. If the subscription is not funded upon issuance, the Company records a stock subscription receivable as an asset on the balance sheet. When stock subscription receivables are not received prior to the issuance of financial statements at a reporting date in satisfaction of the requirements under Accounting Standard Codification (“ASC”) 505-10-45-2, the stock subscription receivable is reclassified as a contra account to stockholder’s deficit on the balance sheet. Reverse Stock Split On December 1, 2022, the Company effected a 1-for-40 reverse stock split of its common stock (the “Reverse Stock Split”). As further described below, at a special meeting of stockholders held on November 30, 2022 (the “Special Meeting”), the stockholders of the Company approved a proposal to authorize the Company’s Board of Directors, in its discretion following the Special Meeting to amend the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”), to effect a reverse stock split of all of the outstanding shares of the Company’s common stock, par value $0.01 per share, at a ratio ranging from any whole number between 1-for-2 and 1-for-40, as determined by the Company’s Board of Directors in its discretion. On November 30, 2022, following the Special Meeting, the Company’s Board of Directors approved the Reverse Stock Split at a ratio of 1-for-40. On December 1, 2022, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment to amend the Company’s Certificate of Incorporation to effect the Reverse Stock Split. The Reverse Stock Split became effective at 5:00 p.m., Eastern Time, on December 1, 2022. As a result of the Reverse Stock Split, every 40 shares of the Company’s common stock issued or outstanding were automatically reclassified into one validly issued, fully-paid and non-assessable new share of common stock, subject to the treatment of fractional shares as described below, without any action on the part of the holders. Proportionate adjustments will be made to the exercise prices and the number of shares underlying the Company’s outstanding equity awards, as applicable, and warrants exercisable for shares of common stock, as well as to the number of shares issuable under the Company’s equity incentive plans and certain existing agreements. The common stock issued pursuant to the Reverse Stock Split remain fully paid and non-assessable. The Reverse Stock Split did not affect the number of authorized shares of common stock or the par value of the common stock. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders of record who would otherwise have been entitled to receive fractional shares as a result of the Reverse Stock Split received a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing sales price per share of the common stock (as adjusted for the Reverse Stock Split) on The Nasdaq Capital Market on November 30, 2022, the last trading day immediately preceding the effective time of the Reverse Stock Split. All share and per share amounts in the accompanying financial statements, related footnotes, and management’s discussion and analysis have been adjusted retroactively to reflect the reverse stock split as if it had occurred at the beginning Recent Accounting Pronouncements Although the FASB has issued several ASUs for which adoption dates are pending, the Company does not expect any to have any material impact on its consolidated financial statements.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	9 Months Ended
	Sep. 30, 2023
Prepaid And Other Current Assets [Abstract]
Prepaid Expenses and Other Current Assets	3. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following (in thousands): September 30, December 31, 2022 Research and development $ 249 $ 366 Insurance 249 93 Other 137 202 Total $ 635 $ 661

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
Accrued Expenses	4. Accrued Expenses Accrued expenses consisted of the following (in thousands): September 30, December 31, 2022 Research and development expenses $ 1,873 $ 1,544 Payroll and other employee-related expenses 122 750 Professional services 278 225 Interest on debt 62 146 Other 107 134 Total $ 2,442 $ 2,799

Debt

Debt	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Debt	. Debt Hercules Term Loan On September 30, 2021, the Company entered into a Loan and Security Agreement, dated as of September 30, 2021 (the “Hercules Loan Agreement”) with Hercules Capital, Inc. (“Hercules” or the “Lender”). The Hercules Loan Agreement provided for term loans in an aggregate principal amount of up to $ 30.0 million, comprised of (i) a tranche 1 advance of $ 12.5 million (the “Tranche 1 Advance”), (ii) a tranche 2 advance of $ 7.5 million (the “Tranche 2 Advance”) and (iii) a tranche 3 advance of $ 10.0 million (the “Tranche 3 Advance”) (collectively, the “Term Loan Advances”). The Tranche 1 Advance under the Hercules Term Loan Agreement was funded on September 30, 2021. The Tranche 2 Advance was to be available at the Company’s election until August 15, 2022, subject to the Company's achievement of certain milestone events relating to data from the clinical trials. The Company did not meet the requirements for the Tranche 2 Advance and such funding will, therefore, not be available to the Company. The Tranche 3 Advance was available subject to approval by the Lenders’ investment committee in its sole discretion up to April 1, 2023, and is also no longer available to the Company. As security for its obligations, the Company granted Hercules a continuing security interest in substantially all of the assets of the Company, subject to certain customary exceptions, including for intellectual property. Any outstanding principal on the Term Loan Advances will accrue interest at a floating rate equal to the greater of (i) 9.50 % per annum and (ii) the sum of 6.25 % plus the prime rate, as published in The Wall Street Journal. As of September 30, 2023 and December 31, 2022, the interest rate was 14.75 % and 13.75 %, respectively. On March 7, 2023, the Company entered into the first Hercules amendment (the "First Hercules Amendment") to repay $ 7.5 million of the outstanding principal of the Hercules Term Loan, extend the interest only period until September 1, 2023, canceled the prepayment penalty for the March principal repayment and any future early principal repayments, and reduced the minimum qualified cash balance amount from $ 10.0 million to $ 2.25 million effective as of March 7, 2023. In accordance with the First Hercules Amendment the Company is required to make principal payments on the outstanding balance of the Term Loan Advances beginning on September 1, 2023, in 20 equal monthly installments, plus interest. Any amounts outstanding under the Term Loan Advances, if not repaid sooner, are due and payable on April 1, 2025 (the “Maturity Date”). On any date that the Company partially repays the outstanding obligations, the Company shall pay the Lenders a charge equal to 6.55% of the original principal amount. The First Hercules Amendment removed this prepayment premium for both the March 7, 2023 principal repayment and for any future early prepayments of principal. The First Hercules Amendment was accounted for as debt modification under ASC 470-50, Debt: Modifications and Extinguishments , with a partial debt extinguishment. The Company recognized a loss on debt extinguishment of $ 0.4 million related to the remaining unamortized debt discount as of the effective date of the First Hercules Amendment during the nine months ended September 30, 2023. The Hercules Loan Agreement contains customary affirmative and negative covenants which, among other things, requires the Company to maintain at all times a minimum qualified cash balance plus qualified accounts payable (defined as invoices that have not been paid within 180 days from the invoice date) and limits the Company’s ability to (i) incur additional indebtedness, (ii) pay dividends or make certain distributions, (iii) dispose of its assets, grant liens or encumber its assets or (iv) fundamentally alter the nature of its business. These covenants are subject to a number of exceptions and qualifications. On May 19, 2023, the Hercules Loan Agreement was amended (the "Second Hercules Amendment") to modify the definition of “Excluded Accounts” under the minimum qualified cash balance covenant to exclude additional accounts from the collateral and related obligations and, on November 10, 2023, the Hercules Loan Agreement was amended (the "Third Hercules Amendment") to temporarily reduce the minimum qualified cash balance amount to $2.25 million for the period from November 15, 2023 through December 15, 2023, unless extended by the Agent under the Hercules Loan Agreement in its sole discretion. After such period, the minimum level of qualified cash will revert to $2.25 million plus the amount of accounts payable that have not been paid within 180 days. The Company was in compliance with all debt covenants at September 30, 2023. The Hercules Loan Agreement also contains customary events of default, including the Company’s failure to make any principal or interest payments when due, the occurrence of certain bankruptcy or insolvency events or a breach of the covenants. Upon the occurrence of an event of default, Hercules may, among other things, accelerate the Company’s obligations under the Hercules Loan Agreement. As of September 30, 2023, the carrying value of the outstanding loan consists of $ 4.8 million in principal less an unamortized debt discount of $ 0.2 million. The debt issuance costs and the final maturity payment of $ 0.8 million, have been recorded as a debt discount, which are being accreted to interest expense through the maturity date of the loan. Interest expense relating to the loan for the three months ended September 30, 2023 and 2022 was $ 0.2 million and $ 0.5 million, respectively, and for the nine months ended September 30, 2023 and 2022 was $ 1.0 million and $ 1.4 million, respectively. Interest expense is calculated using the effective interest method and is inclusive of non-cash amortization of the debt discount. As of September 30, 2023, the effective interest rate was 19.4 %. The Company’s scheduled future principal payments for the long-term debt are as follows (in thousands): At September 30, 2023 Principal payments 2023 $ 681 2024 2,987 2025 1,112 Total future principal payments 4,780 Less unamortized discount ( 159 ) Carrying value of long-term debt 4,621 Less current portion of long-term debt ( 2,819 ) Final fee due at maturity in 2025 819 Long-term portion $ 2,621

Advances From Collaboration Par

Advances From Collaboration Partners, Legal and Other Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Advances From Collaboration Partners, Legal and Other Contingencies	. Advances From Collaboration Partners, Legal and Other Contingencies From time to time, the Company may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. The Company is currently unaware of any material pending legal proceedings to which it is a party or of which its property is the subject. The Company accounts for its contingent liabilities in accordance with ASC Topic 450, “Contingencies”. Cystic Fibrosis Foundation During 2019, the Company received a funding award (the “2019 CFF Award”) from the Cystic Fibrosis Foundation (“CFF”) for up to $ 3.6 million and entered into an agreement relating to the award, which agreement was amended in December 2020 and March 2022. Payment of award amounts are subject to the achievement of certain milestones in connection with the Company’s global cystic fibrosis development program. The Company will be required to repay amounts received from the CFF (or specified multiples of such amounts) in certain circumstances, including as royalties on net sales, and, in the event of a disposition of the underlying asset (as defined in the agreement), in which case the Company would be obliged to use up to 5 % of the amounts received from the disposition to repay up to three times the award amount. The funding provided to the Company is accounted for as an advance from a collaboration partner within the scope of ASC Topic 730, “Research and Development.” In March 2022, the Company entered into an agreement with the CFF to amend the 2019 CFF Award to provide for up to an additional $ 15.9 million to fund the ongoing global Phase 2 clinical development of ELX-02 in cystic fibrosis (the “2022 CFF Amendment”). The Company received $8.5 million during the year ended December 31, 2022, which were recorded as Advances from collaboration partners in the accompanying condensed consolidated financial statements. In July 2023, the Company received a final closeout milestone payment of $ 0.2 million and the remaining $ 7.4 million of the award under the 2022 CFF Amendment will not be available to the Company under the development program. As of September 30, 2023 and December 31, 2022, the Company had received cumulative total payments of $ 12.1 million and $ 11.9 million, respectively, related to the 2019 CFF Award, which are recorded as Advances from collaboration partners in the accompanying condensed consolidated financial statements. In September 2022, the CFF determined not to continue funding this program. Upon successful commercialization of ELX-02 or any derivative products thereof, the Company will pay the CFF royalties up to 6 % of net sales based on the actual amount of funding from the CFF and potential sales milestones. In addition, the 2022 CFF Agreement includes an embedded derivative arising from a provision that upon the occurrence of a change of control or sale or license of funded assets (each a disposition event), the Company would be required to pay the CFF 10 % of the consideration received for the disposition event up to three times the amount of funds received from the CFF under the 2022 CFF Agreement. In May 2021, the Company received an additional award from the CFF (the “2021 CFF Award”) for up to $ 2.6 million to help identify optimized oral RMAs for further development in the treatment of cystic fibrosis patients with nonsense mutations. Payment of award amounts are subject to the achievement of certain milestones in connection with the Company’s oral RMA cystic fibrosis development program. The Company will be required to repay amounts received from the CFF (or specified multiples of such amounts) in certain circumstances, including as royalties on net sales (with royalties capped at eight times the award amount received, the "Royalty Cap"), and, in the event of a disposition of the underlying asset. The funding provided to the Company is accounted for as an advance from a collaboration partner within the scope of ASC Topic 730, “Research and Development.” In August 2023, the Company modified the agreement to among other things, redefine certain milestone goals and increase the license disposition payment from 10 % to 15 %. In August 2023, the Company received a milestone payment of $ 0.2 million. As of September 30, 2023 and December 31, 2022, the Company had received cumulative total payments of $ 0.8 million and $ 0.6 million, respectively, under this award, which are recorded as Advances from collaboration partners in the accompanying consolidated financial statements. As of September 30, 2023, there are up to $1.8 million of milestone payments remaining under this agreement The 2021 CFF Award includes an embedded derivative arising from a provision that upon the occurrence of a change of control or sale or license of funded assets (each a disposition event) the Company would be required to pay the CFF 20 % of the consideration received for the disposition event, and 15 % for a sale or license event (modified in August 2023 from 10 %), up to eight times the amount of funds received from the CFF under the 2021 CFF Agreement. The Company estimated the fair value of the embedded derivatives to be $ 95 thousand and $ 45 thousand as of September 30, 2023 and December 31, 2022, respectively, and has recognized these amounts on the consolidated balance sheets as derivative liabilities with the corresponding change in value of $ 20 thousand and $ 50 thousand expense recognized as the change in fair value of derivative liabilities in other expense, net, in the consolidated statements of operations for the three and nine months ended September 30, 2023, respectively.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Stockholders' Equity	7. Stockholders’ Equity Registered Direct Offering In September 2023, the Company entered into a securities purchase agreement (the “Purchase Agreement”) pursuant to which it sold (i) 305,590 registered shares of its common stock, (ii) pre-funded common stock purchase warrants (the “Pre-Funded Warrants”) to purchase up to 75,000 shares of common stock, at an exercise price of $ 0.001 per share, and (iii) warrants (the "September 2023 Warrants") to purchase up to 380,590 shares of common stock, at an exercise price of $ 5.13 per share, in a private placement, for total gross proceeds of $ 2.0 million (the “September 2023 Registered Direct Offering”). The September 2023 Registered Direct Offering closed on September 20, 2023. The September 2023 Pre-Funded Warrants became exercisable upon issuance and are exercisable until exercised in full. The September 2023 Warrants became exercisable upon issuance and expire 5.5 years after the date of issuance. In connection with the September 2023 Registered Direct Offering, the Company also granted warrants to the placement agent ("Placement Agent Warrants") to purchase a total of 22,835 shares of common stock that have an exercise price per share equal to $ 6.5688 and a term of five years. The September 2023 Warrants are classified as liabilities within Level 3 due to certain early settlement provisions that preclude them from equity classification due to not being considered indexed to the Company’s own stock since such an input could result in a settlement amount that is greater than the settlement amount of a fixed-for-fixed option on the Company’s equity shares. The value of the September 2023 Warrants was determined to be $ 1.9 million, calculated using a Monte Carlo simulation on September 20, 2023 with the following assumptions: volatility of 139 %, stock price of $ 5.40 , risk-free rate of 4.7 %, and a term of 3.0 years. The Placement Agent Warrants were issued for services performed by the placement agent as part of the September 2023 Registered Direct Offering and were accounted for as offering costs. The Placement Agent Warrants are classified as liabilities within Level 3 due to certain early settlement provisions that preclude them from equity classification due to not being considered indexed to the Company’s own stock since such an input could result in a settlement amount that is greater than the settlement amount of a fixed-for-fixed option on the Company’s equity shares. The value of the Placement Agent Warrants was determined to be $ 0.1 million, calculated using a Monte Carlo simulation on September 20, 2023 with the following assumptions: volatility of 139 %, stock price of $ 5.40 , risk-free rate of 4.7 %, and a term of 3.0 years. In addition to the value of the Placement Agent Warrants, the Company incurred additional offering costs totaling $ 0.3 million tha t consist of placement agent fees and direct incremental legal, advisory, accounting and filing fees relating to the September 2023 Registered Direct Offering, resulting in net cash proceeds of $ 1.7 million. As the value of the September 2023 Warrants exceeded the net proceeds received, the entire proceeds were allocated to the September 2023 Warrants liability, resulting in a loss on issuance of common stock of $ 0.2 million, which was recorded in Other Expense (Income) in the consolidated statements of operation. ATM Program On May 24, 2023, the Company entered into a Sales Agreement (the “Oppenheimer Sales Agreement”) with Oppenheimer & Co. Inc. (“Oppenheimer”) pursuant to which the Company may, subject to the offering limits of General Instruction I.B.6 to Form S-3 (as applicable), offer and sell shares of its common stock (the “ATM Shares”), having aggregate gross sales proceeds of up to $ 50.0 million, from time to time, through an “at the market offering” program (the ""ATM Program") under which Oppenheimer will act as sales agent. The shares of Common Stock that may be sold pursuant to the Oppenheimer Sales Agreement will be issued pursuant to the Company’s shelf registration statement on Form S-3. As of May 24, 2023, the date of the Company’s prospectus supplement relating to the sale of common stock under the ATM Program, the Company may only offer and sell shares of its Common Stock having an aggregate offering price of up to $ 6.5 million pursuant to the Oppenheimer Sales Agreement, of which $ 3.5 million has been sold as of the date of this Quarterly Report on Form 10-Q. The Company has agreed to pay Oppenheimer a commission up to 3.0 % of the gross sales proceeds of any shares of Common Stock sold through Oppenheimer under the Oppenheimer Sales Agreement, and also has provided Oppenheimer with customary indemnification and contribution rights. The Oppenheimer Sales Agreement may be terminated at any time by either party upon prior written notice to the other party. The Company is not obligated to make any sales of Shares under the Oppenheimer Sales Agreement. The offering of Shares pursuant to the Oppenheimer Sales Agreement will terminate upon the earlier of (i) the sale of all Common Stock subject to the Oppenheimer Sales Agreement or (ii) termination of the Oppenheimer Sales Agreement in accordance with its terms. During the three and nine months ended September 30, 2023, the Company has sold 270,134 and 596,44 shares of common stock through the ATM Program, respectively, for gross proceeds of $ 1.8 million and $ 3.5 million, respectively, or a weighted average share price of $ 6.68 and $ 5.87 per share, respectively. The Company recognized issuance costs of $ 0.1 million and 0.3 million during the three and nine-months ended September 30, 2023, respectively, related to the ATM Program, which were accounted for as a reduction of proceeds. Warrants Following is a summary of outstanding warrants as of September 30, 2023 and warrant transaction activity d uring the nine months ended September 30, 2023. Issuance Date Term (years) Exercise Price Warrants Outstanding at December 31, 2022 Warrants Exercised During 2023 Warrants Outstanding at September 30, 2023 Classification SVB Warrants January 20, 2019 10 $ 440.80 1,021 — 1,021 Equity September 2023 Warrants September 20, 2023 5.5 $ 5.13 — — 380,590 Liability Placement Agent Warrants September 20, 2023 5 $ 6.5688 — — 22,835 Liability Pre-Funded Warrants September 20, 2023 Perpetual $ 0.001 — — 75,000 Equity 1,021 — 479,446

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	8. Stock-based Compensation Summary of Stock Option Activity Transactions related to stock options awarded to employees and directors during the nine months ended September 30, 2023 were as follows: Shares Weighted Weighted Aggregate Options outstanding at December 31, 2022 249,403 $ 105.87 8.12 $ 3 Granted 221,395 4.27 Forfeited ( 59,413 ) 17.06 Options outstanding at September 30, 2023 411,385 $ 64.02 6.48 $ 9 Options exercisable at September 30, 2023 132,907 $ 152.74 5.38 $ 9 The aggregate intrinsic value represents the total intrinsic value (the difference between the fair value of the common stock as of September 30, 2023 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on September 30, 2023. This amount is impacted by changes in the fair value of the common stock. Summary of Restricted Stock Unit Activity Activity related to restricted stock units awarded to employees during the nine months ended September 30, 2023 were as follows: Shares Weighted Average Grant Date Fair Value Per Share Unvested at December 31, 2022 — $ — Granted 75,000 4.29 Unvested at September 30, 2023 75,000 $ 4.29 Stock-based Compensation Stock-based compensation relates to employees, non-employee directors and non-employee consultants, time-based stock options and restricted stock units granted. Total stock-based compensation expense related to all of the Company’s stock-based awards was recognized as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Research and development $ 54 $ 328 $ 629 $ 1,013 General and administrative 364 386 996 1,367 Total stock-based compensation expense $ 418 $ 714 $ 1,625 $ 2,380

Recurring Fair Value Measuremen

Recurring Fair Value Measurements	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Recurring Fair Value Measurements	. Recurring Fair Value Measurements The following tables summarize the Company's fair value hierarchy for its financial assets and liabil ities measured at fair value on a recurring basis (in thousands): As of September 30, 2023 Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Money market funds included in cash and cash equivalents $ 665 $ 665 $ — $ — Liabilities Embedded derivatives $ 95 $ — $ — $ 95 Warrant liabilities 1,695 — — 1,695 As of December 31, 2022 Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Money market funds included in cash and cash equivalents $ 18,737 $ 18,737 $ — $ — Liabilities Embedded derivatives $ 45 $ — $ — $ 45 As described in Note 7, the Company issued Common Warrants and Placement Agent Warrants as part of the September 2023 Registered Direct Offering which are classified as liabilities within Level 3 due to certain early settlement provisions that preclude them from equity classification. The value of the September 2023 Warrants was determined to be $1.6 million, calculated using a Monte Carlo simulation on September 30, 2023 with the following assumptions: volatility of 139%, stock price of $4.81, risk-free rate of 4.7% and a term of 3.0 years. The value of the Placement Agent Warrants was determined to be $0.1 million, calculated using a Monte Carlo simulation on September 30, 2023 with the following assumptions: volatility of 139%, stock price of $4.81, risk-free rate of 4.7% and a term of 3.0 years. The table below provides a summary of the fair value of the warrant derivative liabilities, a Level 3 fair value estimate (in thousands), for the three and nine months ended September 30, 2023 and 2022: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Fair value of warrant liabilities, beginning of period $ — $ — $ — $ — Issuance of 2023 Common Warrants and Placement Agent Warrants 1,968 — 1,968 — Change in fair value of Common Warrants and Placement Agent Warrants ( 273 ) — ( 273 ) — Fair value of warrant liabilities, end of period $ 1,695 $ — $ 1,695 $ — The Company is party to certain funding awards with the CFF, which contain embedded derivatives (refer to Note 6). As of the balance sheet date, the Company has determined the fair value of these embedded derivatives using a Monte Carlo simulation of the occurrence of a disposition event. The Company has used observable input assumptions such as the amount of funding, the Royalty Cap, as well as unobservable assumptions such as the time to occurrence of three years, as well as the probability of occurrence of a disposition event. The table below provides a summary of the fair value of the embedded derivatives, a Level 3 fair value estimate (in thousands), for the three and nine months ended September 30, 2023 and 2022: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Fair value of embedded derivatives, beginning of period $ 75 $ 166 $ 45 $ — Change in fair value of embedded derivative liabilities 20 ( 50 ) 50 116 Fair value of embedded derivatives, end of period $ 95 $ 116 $ 95 $ 116

Other Expense (Income), Net

Other Expense (Income), Net	9 Months Ended
	Sep. 30, 2023
Other Income and Expenses [Abstract]
Other Expense, Net	10. Other Expense (Income), Net Other (income) expense, net consisted of the following (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Interest expense $ 235 $ 489 $ 950 $ 1,368 Interest income ( 20 ) ( 108 ) ( 245 ) ( 133 ) Loss on debt extinguishment — — 406 — Loss on issuance of common stock 231 — 231 — Gain on sale of fixed assets ( 255 ) — ( 255 ) — Foreign currency exchange losses (gains) 3 35 33 4 Change in fair value of derivative liabilities 20 ( 50 ) 50 116 Change in fair value of warrant liabilities ( 273 ) — ( 273 ) — Other expense 14 — 6 — Total other (income) expense, net $ ( 45 ) $ 366 $ 903 $ 1,355

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Net Loss Per Share	11. Net Loss Per Share The net loss and the weighted average number of shares used in computing basic and diluted net loss per share for the periods, are as follows (amounts in thousands, except share and per share data): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Numerator: Net loss $ ( 3,592 ) $ ( 7,508 ) $ ( 14,163 ) $ ( 29,746 ) Denominator: Weighted average number of shares of 2,747,687 2,166,404 2,377,599 2,166,344 Net loss per share, basic and diluted $ ( 1.31 ) $ ( 3.47 ) $ ( 5.96 ) $ ( 13.73 ) The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as their effect would be anti-dilutive: Nine Months Ended September 30, 2023 2022 Options to purchase common stock 411,385 263,211 Restricted stock units 75,000 — Common warrants 404,446 1,021 Total potential common stock equivalents 890,831 264,232 The 75,000 Pre-Funded Common Warrants are exercisable for only a de minimis cash consideration with no substantive exercise contingencies, as such, the Company determined the Pre-Funded Common Warrants should be considered as outstanding shares for both basic and diluted EPS calculations.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements Although the FASB has issued several ASUs for which adoption dates are pending, the Company does not expect any to have any material impact on its consolidated financial statements.
Reverse Stock Split	Reverse Stock Split On December 1, 2022, the Company effected a 1-for-40 reverse stock split of its common stock (the “Reverse Stock Split”). As further described below, at a special meeting of stockholders held on November 30, 2022 (the “Special Meeting”), the stockholders of the Company approved a proposal to authorize the Company’s Board of Directors, in its discretion following the Special Meeting to amend the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”), to effect a reverse stock split of all of the outstanding shares of the Company’s common stock, par value $0.01 per share, at a ratio ranging from any whole number between 1-for-2 and 1-for-40, as determined by the Company’s Board of Directors in its discretion. On November 30, 2022, following the Special Meeting, the Company’s Board of Directors approved the Reverse Stock Split at a ratio of 1-for-40. On December 1, 2022, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment to amend the Company’s Certificate of Incorporation to effect the Reverse Stock Split. The Reverse Stock Split became effective at 5:00 p.m., Eastern Time, on December 1, 2022. As a result of the Reverse Stock Split, every 40 shares of the Company’s common stock issued or outstanding were automatically reclassified into one validly issued, fully-paid and non-assessable new share of common stock, subject to the treatment of fractional shares as described below, without any action on the part of the holders. Proportionate adjustments will be made to the exercise prices and the number of shares underlying the Company’s outstanding equity awards, as applicable, and warrants exercisable for shares of common stock, as well as to the number of shares issuable under the Company’s equity incentive plans and certain existing agreements. The common stock issued pursuant to the Reverse Stock Split remain fully paid and non-assessable. The Reverse Stock Split did not affect the number of authorized shares of common stock or the par value of the common stock. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders of record who would otherwise have been entitled to receive fractional shares as a result of the Reverse Stock Split received a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing sales price per share of the common stock (as adjusted for the Reverse Stock Split) on The Nasdaq Capital Market on November 30, 2022, the last trading day immediately preceding the effective time of the Reverse Stock Split. All share and per share amounts in the accompanying financial statements, related footnotes, and management’s discussion and analysis have been adjusted retroactively to reflect the reverse stock split as if it had occurred at the beginning

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2023
Prepaid And Other Current Assets [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following (in thousands): September 30, December 31, 2022 Research and development $ 249 $ 366 Insurance 249 93 Other 137 202 Total $ 635 $ 661

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
Accrued expenses	Accrued expenses consisted of the following (in thousands): September 30, December 31, 2022 Research and development expenses $ 1,873 $ 1,544 Payroll and other employee-related expenses 122 750 Professional services 278 225 Interest on debt 62 146 Other 107 134 Total $ 2,442 $ 2,799

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Schedule of Future Principal Payments for Long-Term Debt	At September 30, 2023 Principal payments 2023 $ 681 2024 2,987 2025 1,112 Total future principal payments 4,780 Less unamortized discount ( 159 ) Carrying value of long-term debt 4,621 Less current portion of long-term debt ( 2,819 ) Final fee due at maturity in 2025 819 Long-term portion $ 2,621

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Summary of Warrants Outstanding	uring the nine months ended September 30, 2023. Issuance Date Term (years) Exercise Price Warrants Outstanding at December 31, 2022 Warrants Exercised During 2023 Warrants Outstanding at September 30, 2023 Classification SVB Warrants January 20, 2019 10 $ 440.80 1,021 — 1,021 Equity September 2023 Warrants September 20, 2023 5.5 $ 5.13 — — 380,590 Liability Placement Agent Warrants September 20, 2023 5 $ 6.5688 — — 22,835 Liability Pre-Funded Warrants September 20, 2023 Perpetual $ 0.001 — — 75,000 Equity 1,021 — 479,446

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Transactions Related to Stock Options Awarded to Employees and Directors	Transactions related to stock options awarded to employees and directors during the nine months ended September 30, 2023 were as follows: Shares Weighted Weighted Aggregate Options outstanding at December 31, 2022 249,403 $ 105.87 8.12 $ 3 Granted 221,395 4.27 Forfeited ( 59,413 ) 17.06 Options outstanding at September 30, 2023 411,385 $ 64.02 6.48 $ 9 Options exercisable at September 30, 2023 132,907 $ 152.74 5.38 $ 9
Activity Related to Restricted Stock Units Awarded to Employees	Activity related to restricted stock units awarded to employees during the nine months ended September 30, 2023 were as follows: Shares Weighted Average Grant Date Fair Value Per Share Unvested at December 31, 2022 — $ — Granted 75,000 4.29 Unvested at September 30, 2023 75,000 $ 4.29
Summary of Allocated Stock-based Compensation Expense	Total stock-based compensation expense related to all of the Company’s stock-based awards was recognized as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Research and development $ 54 $ 328 $ 629 $ 1,013 General and administrative 364 386 996 1,367 Total stock-based compensation expense $ 418 $ 714 $ 1,625 $ 2,380

Recurring Fair Value Measurem_2

Recurring Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of Assets and liabilities measured at fair value on a recurring basis	The following tables summarize the Company's fair value hierarchy for its financial assets and liabil ities measured at fair value on a recurring basis (in thousands): As of September 30, 2023 Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Money market funds included in cash and cash equivalents $ 665 $ 665 $ — $ — Liabilities Embedded derivatives $ 95 $ — $ — $ 95 Warrant liabilities 1,695 — — 1,695 As of December 31, 2022 Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Money market funds included in cash and cash equivalents $ 18,737 $ 18,737 $ — $ — Liabilities Embedded derivatives $ 45 $ — $ — $ 45
Schedule of the Fair Value of the Warrant Derivative Liabilities	The table below provides a summary of the fair value of the warrant derivative liabilities, a Level 3 fair value estimate (in thousands), for the three and nine months ended September 30, 2023 and 2022: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Fair value of warrant liabilities, beginning of period $ — $ — $ — $ — Issuance of 2023 Common Warrants and Placement Agent Warrants 1,968 — 1,968 — Change in fair value of Common Warrants and Placement Agent Warrants ( 273 ) — ( 273 ) — Fair value of warrant liabilities, end of period $ 1,695 $ — $ 1,695 $ —
Summary of Rollforward of Fair Value of Embedded Derivatives	The table below provides a summary of the fair value of the embedded derivatives, a Level 3 fair value estimate (in thousands), for the three and nine months ended September 30, 2023 and 2022: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Fair value of embedded derivatives, beginning of period $ 75 $ 166 $ 45 $ — Change in fair value of embedded derivative liabilities 20 ( 50 ) 50 116 Fair value of embedded derivatives, end of period $ 95 $ 116 $ 95 $ 116

Other Expense (Income), Net (Ta

Other Expense (Income), Net (Tables)	9 Months Ended
	Sep. 30, 2023
Other Income and Expenses [Abstract]
Schedule of Other expense (income), net	Other (income) expense, net consisted of the following (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Interest expense $ 235 $ 489 $ 950 $ 1,368 Interest income ( 20 ) ( 108 ) ( 245 ) ( 133 ) Loss on debt extinguishment — — 406 — Loss on issuance of common stock 231 — 231 — Gain on sale of fixed assets ( 255 ) — ( 255 ) — Foreign currency exchange losses (gains) 3 35 33 4 Change in fair value of derivative liabilities 20 ( 50 ) 50 116 Change in fair value of warrant liabilities ( 273 ) — ( 273 ) — Other expense 14 — 6 — Total other (income) expense, net $ ( 45 ) $ 366 $ 903 $ 1,355

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Schedule of Net Loss and Weighted Average Number of Shares Used in Computing Basic and Diluted Net Loss Per Share	The net loss and the weighted average number of shares used in computing basic and diluted net loss per share for the periods, are as follows (amounts in thousands, except share and per share data): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Numerator: Net loss $ ( 3,592 ) $ ( 7,508 ) $ ( 14,163 ) $ ( 29,746 ) Denominator: Weighted average number of shares of 2,747,687 2,166,404 2,377,599 2,166,344 Net loss per share, basic and diluted $ ( 1.31 ) $ ( 3.47 ) $ ( 5.96 ) $ ( 13.73 )
Potentially Dilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding	The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as their effect would be anti-dilutive: Nine Months Ended September 30, 2023 2022 Options to purchase common stock 411,385 263,211 Restricted stock units 75,000 — Common warrants 404,446 1,021 Total potential common stock equivalents 890,831 264,232

Nature of the Business - Additi

Nature of the Business - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 07, 2023	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Accumulated deficit		$ 288,551	$ 274,388
Aggregate principal amount of initial loan advance		4,621
Cash, cash equivalents and marketable securities		$ 4,800
Hercules Term Loan Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Principal amount	$ 7,500
Minimum Qualified Cash Balance	2,250
Hercules Term Loan Agreement [Member] | Tranche 1 Advance [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Aggregate principal amount of initial loan advance			12,500	$ 12,500
Hercules Term Loan Agreement [Member] | Maximum [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Minimum Qualified Cash Balance	$ 10,000
Aggregate principal amount of initial loan advance			$ 30,000	$ 30,000

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Research and development	$ 249	$ 366
Insurance	249	93
Other	137	202
Total	$ 635	$ 661

Accrued Expenses - Accrued Expe

Accrued Expenses - Accrued Expenses (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Research and development expenses	$ 1,873	$ 1,544
Payroll and other employee-related expenses	122	750
Professional services	278	225
Interest on debt	62	146
Other	107	134
Total	$ 2,442	$ 2,799

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Mar. 07, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Sep. 30, 2021
Debt Instrument [Line Items]
Aggregate principal amount of initial loan advance		$ 4,621		$ 4,621
Loan, interest rate						13.75%
Loan, principal outstanding		4,780		4,780
Loan, unamortized debt discount		159		159
Loan, final maturity payment		$ 819		$ 819
Hercules Term Loan Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate terms				Any outstanding principal on the Term Loan Advances will accrue interest at a floating rate equal to the greater of (i) 9.50% per annum and (ii) the sum of 6.25% plus the prime rate, as published in The Wall Street Journal. As of September 30, 2023 and December 31, 2022, the interest rate was 14.75% and 13.75%, respectively.
Outstanding principal value	$ 7,500
Loss on debt extinguishment				$ 400
Loan, floating interest rate				9.50%
Loan, interest rate		14.75%		14.75%
Loan, principal outstanding		$ 4,800		$ 4,800
Minimum qualified cash balance	2,250
Loan, unamortized debt discount		200		200
Loan, interest expense		$ 200	$ 500	$ 1,000	$ 1,400
Loan, effective interest rate		19.40%		19.40%
Loan, final maturity payment		$ (800)		$ (800)
Gain (loss) on extinguishment of debt				$ 400
Hercules Term Loan Agreement [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Loan, floating interest rate				6.25%
Hercules Term Loan Agreement [Member] | Minimum [Member]
Debt Instrument [Line Items]
Qualified cash balance	10,000
Hercules Term Loan Agreement [Member] | Maximum [Member]
Debt Instrument [Line Items]
Aggregate principal amount of initial loan advance						$ 30,000	$ 30,000
Qualified cash balance	2,250
Minimum qualified cash balance	$ 10,000
Hercules Term Loan Agreement [Member] | Tranche 1 Advance [Member]
Debt Instrument [Line Items]
Aggregate principal amount of initial loan advance						$ 12,500	12,500
Hercules Term Loan Agreement [Member] | Tranche 3 Advance [Member]
Debt Instrument [Line Items]
Aggregate principal amount of initial loan advance							10,000
Hercules Term Loan Agreement [Member] | Tranche 2 Advance [Member]
Debt Instrument [Line Items]
Aggregate principal amount of initial loan advance							$ 7,500

Debt - Schedule of Future Princ

Debt - Schedule of Future Principal Payments for Long-Term Debt (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
2023	$ 681
2024	2,987
2025	1,112
Total future principal payments	4,780
Less unamortized discount	(159)
Carrying value of long-term debt	4,621
Less current portion of long-term debt	(2,819)	$ (3,980)
Final fee due at maturity in 2023	819
Long-term portion	$ 2,621	$ 8,557

Advances From Collaboration P_2

Advances From Collaboration Partners, Legal and Other Contingencies - Additional Information (Detail) $ in Thousands		1 Months Ended		3 Months Ended	9 Months Ended	12 Months Ended
	Aug. 31, 2023	Jul. 31, 2023 USD ($)	May 31, 2021 USD ($)	Sep. 30, 2023 USD ($) Time	Sep. 30, 2023 USD ($) Time	Dec. 31, 2022 USD ($)
Royalties percentage of net sales based on actual amount of funding					6%
Maximum [Member]
Related Party Transaction Percentage Of Expenses					5%
Two Thousand Nineteen Cystic Fibrosis Foundation Award [Member]
Other Liabilities, Current				$ 12,100	$ 12,100	$ 11,900
Two Thousand Nineteen Cystic Fibrosis Foundation Award [Member] | Maximum [Member]
Funding award amount received					$ 3,600
Two Thousand Twenty Two Cystic Fibrosis Foundation Agreement [Member]
Number of times amount of funds received | Time				3	3
Two Thousand Twenty Two Cystic Fibrosis Foundation Agreement [Member] | Elox - Liabilities [Member]
Other Liabilities, Current				$ 95	$ 95	45
Embedded derivative, gain (loss) on embedded derivative, net				20	50
Two Thousand Twenty Two Cystic Fibrosis Foundation Agreement [Member] | Elox - Cystic Fibrosis Foundation [Member]
Aggregate milestone payment					$ 200	200
Percentage Of Consideration Received For Disposition Event					10%
Two Thousand Twenty Two Cystic Fibrosis Foundation Agreement [Member] | Elox - Cystic Fibrosis Foundation [Member] | Elox - Phase Two Clinical Development [Member]
Aggregate milestone payment		$ 200
Remaining amount of award payable upon achievement certain clinical development milestones					$ 7,400
Two Thousand Twenty Two Cystic Fibrosis Foundation Agreement [Member] | Elox - Cystic Fibrosis Foundation [Member] | Elox - Phase Two Clinical Development [Member] | Maximum [Member]
Award to fund development milestones					15,900
Two Thousand Twenty One Cystic Fibrosis Foundation Award [Member]
Other Liabilities, Current				$ 800	$ 800	$ 600
Two Thousand Twenty One Cystic Fibrosis Foundation Award [Member] | Maximum [Member]
Funding award amount received			$ 2,600
Percentage Of License Disposition Payment	15%
Two Thousand Twenty One Cystic Fibrosis Foundation Award [Member] | Minimum [Member]
Percentage Of License Disposition Payment	10%
Two Thousand Twenty One Cystic Fibrosis Foundation Award [Member] | Elox - Cystic Fibrosis Foundation [Member]
Percentage Of Consideration Received For Disposition Event					20%
Percentage of sale or license event	10%				15%

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Transactions Related to Warrants (Details) - $ / shares	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Term (years)	5 years 6 months
Warrants Outstanding	479,446	1,021
SVB Warrants | Equity
Class of Stock [Line Items]
Issuance Date	Jan. 20, 2019
Term (years)	10 years
Exercise Price	$ 440.8
Warrants Outstanding	1,021	1,021
September 2023 Warrants | Liability
Class of Stock [Line Items]
Issuance Date	Sep. 20, 2023
Term (years)	5 years 6 months
Exercise Price	$ 5.13
Warrants Outstanding	380,590	0
Placement Agent Warrants | Liability
Class of Stock [Line Items]
Issuance Date	Sep. 20, 2023
Term (years)	5 years
Exercise Price	$ 6.5688
Warrants Outstanding	22,835	0
Pre-Funded Warrants | Equity
Class of Stock [Line Items]
Issuance Date	Sep. 20, 2023
Exercise Price	$ 0.001
Warrants Outstanding	75,000	0

Stockholder's Equity - Addition

Stockholder's Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended			6 Months Ended	9 Months Ended
	May 24, 2023	Sep. 30, 2023	Jun. 30, 2023	Sep. 30, 2022	Jun. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Mar. 31, 2023	Dec. 31, 2022
Class Of Stock [Line Items]
Common Stock, Shares Authorized		500,000,000				500,000,000			500,000,000
Common Stock, Shares, Issued		3,068,390				3,068,390			3,068,390
Deferred Offering Costs		$ 300				$ 300
Loss on Issuance of Common Stock		231		$ 0		231	$ 0
Net cash proceeds						$ 1,700
Weighted average remaining contractual life						5 years 6 months
Sale of common stock through ATM, net of issuance costs		1,722	$ 1,428			$ 3,150	$ 0
Issuance cost		$ 124	$ 228	$ 263
Black-Scholes model [Member]
Class Of Stock [Line Items]
Proceeds from Issuance of Warrants						$ 1,900
volatility		139%				139%
Risk-Free Rate						4.70%
Weighted average exercise price		$ 5.4				$ 5.4
Weighted average remaining contractual life						3 years
Sales Agreement [Member]
Class Of Stock [Line Items]
Sale of Stock, Price Per Share		$ 5.87				$ 5.87		$ 6.68
Sale of common stock through ATM, net of issuance costs	$ 3,500	$ 1,800			$ 3,500
Stock Price		$ 5.87				$ 5.87		$ 6.68
Issuance cost		$ 100				$ 300
September 2023 Warrants [Member]
Class Of Stock [Line Items]
Weighted average exercise price		$ 5.13				$ 5.13
Purchase Agreement [Member]
Class Of Stock [Line Items]
Common Stock, Shares, Issued		305,590				305,590
Total Gross Proceeds						$ 2,000
Weighted average exercise price		$ 0.001				$ 0.001
Placement Agent Warrants [Member]
Class Of Stock [Line Items]
Common Stock, Shares Authorized		22,835				22,835
Weighted average exercise price		$ 6.5688				$ 6.5688
Placement Agent Warrants [Member] | Black-Scholes model [Member]
Class Of Stock [Line Items]
Proceeds from Issuance of Warrants						$ 100
volatility		139%				139%
Risk-Free Rate						4.70%
Weighted average exercise price		$ 5.4				$ 5.4
Weighted average remaining contractual life						3 years
ATM Program [Member]
Class Of Stock [Line Items]
Issuance of shares upon public offering, shares		270,134				59,644
Maximum [Member] | Sales Agreement [Member]
Class Of Stock [Line Items]
Sale of stock, authorized amount of common stock	50,000
Aggregate offering price	$ 6,500
Percentage Of Sales Agents Commission On Gross Proceeds Of Sales Of Common Stock	3%
Maximum [Member] | September 2023 Warrants [Member]
Class Of Stock [Line Items]
Number of common stock in warrant		380,590				380,590
Maximum [Member] | Purchase Agreement [Member]
Class Of Stock [Line Items]
Number of common stock in warrant		75,000				75,000

Stock-based Compensation - Tran

Stock-based Compensation - Transactions Related to Stock Options Awarded to Employees and Directors (Detail) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Amount
Options outstanding at December 31, 2022	249,403
Granted	221,395
Forfeited	(59,413)
Options outstanding at June 30, 2023	411,385	249,403
Options exercisable at June 30, 2023	132,907
Weighted average exercise price
Options outstanding at December 31, 2022	$ 105.87
Granted	4.27
Forfeited	17.06
Options outstanding at June 30, 2023	64.02	$ 105.87
Options exercisable at June 30, 2023	$ 152.74
Weighted average remaining contractual life
Options outstanding	6 years 5 months 23 days	8 years 1 month 13 days
Options exercisable	5 years 4 months 17 days
Aggregate intrinsic value
Options outstanding	$ 9	$ 3
Options exercisable	$ 9

Stock-based Compensation - Acti

Stock-based Compensation - Activity Related to Restricted Stock Units Awarded to Employees (Detail)	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Amount
Unvested at December 31, 2022 | shares	0
Granted | shares	75,000
Unvested at September 30, 2023 | shares	75,000
Weighted average grant date fair value price
Unvested at December 31, 2022 | $ / shares	$ 0
Granted | $ / shares	4.29
Unvested at September 30, 2023 | $ / shares	$ 4.29

Stock-based Compensation - Summ

Stock-based Compensation - Summary of Allocated Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 418	$ 714	$ 1,625	$ 2,380
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	54	328	629	1,013
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 364	$ 386	$ 996	$ 1,367

Recurring Fair Value Measurem_3

Recurring Fair Value Measurements - Schedule of Assets and liabilities measured at fair value on a recurring basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative Liability	$ 95	$ 45
Warrant liabilities	1,695
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative Liability	95	45
Warrant liabilities	1,695
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	665	18,737
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	$ 665	$ 18,737

Recurring Fair Value Measurem_4

Recurring Fair Value Measurements - Schedule of the Fair Value of the Warrant Derivative Liabilities (Details) - Fair Value, Inputs, Level 3 [Member] - Warrants [Member] - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Issuance of 2023 Common Warrants and Placement Agent Warrants	$ 1,968	$ 1,968
Change in fair value of Common Warrants and Placement Agent Warrants	(273)	(273)
Fair value of warrant liabilities, end of period	$ 1,695	$ 1,695

Recurring Fair Value Measurem_5

Recurring Fair Value Measurements - Summary of Rollforward of Fair Value of Embedded Derivatives (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Change in fair value of derivative liabilities	$ 20	$ (50)	$ 50	$ 116
Monte Carlo Simulation [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value of embedded derivatives, beginning of period	75	166	45	0
Change in fair value of derivative liabilities	(20)	(50)	(50)	116
Fair value of embedded derivatives, end of period	$ 95	$ 116	$ 95	$ 116

Other expense (income), net - S

Other expense (income), net - Schedule of Other (income) expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Other Income and Expenses [Abstract]
Interest expense	$ 235	$ 489	$ 950	$ 1,368
Interest income	(20)	(108)	(245)	(133)
Loss on debt extinguishment	0	0	406	0
Loss on issuance of common stock	231	0	231	0
Gain on sale of fixed assets	(255)	0	(255)	0
Foreign currency exchange losses (gains)	3	35	33	4
Change in fair value of derivative liabilities	20	(50)	50	116
Change in fair value of warrant liabilities	(273)	0	(273)	0
Other (income) expense	14	0	6	0
Total other expense, net	$ (45)	$ 366	$ 903	$ 1,355

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Net Loss and Weighted Average Number of Shares Used in Computing Basic and Diluted Net Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Numerator:
Net loss	$ (3,592)	$ (4,341)	$ (6,230)	$ (7,508)	$ (10,618)	$ (11,620)	$ (14,163)	$ (29,746)
Denominator:
Weighted average number of shares of common stock used in computing net loss per share, basic	2,747,687			2,166,404			2,377,599	2,166,344
Weighted average number of shares of common stock used in computing net loss per share, diluted	2,747,687			2,166,404			2,377,599	2,166,344
Net loss per share, basic	$ (1.31)			$ (3.47)			$ (5.96)	$ (13.73)
Net loss per share, diluted	$ (1.31)			$ (3.47)			$ (5.96)	$ (13.73)

Net Loss Per Share - Potentiall

Net Loss Per Share - Potentially Dilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding (Detail) - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential common stock equivalents	890,831	264,232
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential common stock equivalents	411,385	263,211
Restricted Stock Units [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential common stock equivalents	75,000	0
Warrants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential common stock equivalents	404,446	1,021

Net Loss Per Share (Additional

Net Loss Per Share (Additional Information) (Details)	Sep. 30, 2023 shares
Class of Warrant or Right [Line Items]
Pre Funded Common Warrants	75,000